Based: Waltham, MA
Raised: $58.3 million
Investors: InterWest Partners, Kleiner Perkins Caufield & Byers, New Enterprise Associates, Pappas Ventures, T. Rowe Price Threshold Partnerships, Undisclosed Investors, Venrock Associates

The scoop: The cash that arrived ahead of Tesaro's successful IPO was the second tranche of its whopping $101 million round announced last year. Tesaro is distinctly different from many of the biotechs making a risky leap into the public markets these days. Its executive team, led by Lonnie Moulder, orchestrated the $3.9 billion sale of MGI Pharma. Tesaro nabbed niraparib, a cancer drug in Merck's ($MRK) pipeline, recently. It has also in-licensed rolapitant and pushed the cancer treatment into a Phase III study, with an eye to delivering top-line data in the second half of next year. Tesaro was named a Fierce 15 company in 2011.


Suggested Articles

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.

Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.

The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.